Elephas Biosciences partners with Tes Pharma to evaluate TES-4207 in lung cancer tumor tissue

PUBT · 1d ago
Elephas Biosciences partners with Tes Pharma to evaluate TES-4207 in lung cancer tumor tissue
  • Elephas Biosciences entered a collaboration with Tes Pharma to support development of TES-4207 for non-small cell lung cancer.
  • Tes Pharma will use Elephas’ elive platform to measure ex vivo drug response in live human NSCLC tumor fragments.
  • Work will assess TES-4207 as a monotherapy, with separate testing in combination with immune checkpoint inhibitors, including PD-1 blockade.
  • Functional response data will be used to profile responders versus non-responders, informing translational work, mechanism studies, combination strategy, clinical development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elephas Biosciences Corp. published the original content used to generate this news brief on September 24, 2026, and is solely responsible for the information contained therein.